Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Shares Issued (2018 - 2025)

UroGen Pharma's Shares Issued history spans 8 years, with the latest figure at $31.8 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 124.02% year-over-year to $31.8 million; the TTM value through Dec 2025 reached $40.0 million, up 114.76%, while the annual FY2025 figure was $39.8 million, 113.51% up from the prior year.
  • Shares Issued reached $31.8 million in Q4 2025 per URGN's latest filing, up from $8.2 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $80.1 million in Q2 2024 to a low of -$132.5 million in Q4 2024.
  • Average Shares Issued over 5 years is $4.0 million, with a median of $16000.0 recorded in 2022.
  • Peak YoY movement for Shares Issued: crashed 633.33% in 2022, then soared 421087.5% in 2023.
  • A 5-year view of Shares Issued shows it stood at $3000.0 in 2021, then plummeted by 633.33% to -$16000.0 in 2022, then tumbled by 415431.25% to -$66.5 million in 2023, then tumbled by 99.34% to -$132.5 million in 2024, then skyrocketed by 124.02% to $31.8 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Shares Issued are $31.8 million (Q4 2025), $8.2 million (Q3 2025), and -$1000.0 (Q2 2025).